Skip to main content

Advertisement

Log in

Correlation of Serum-Soluble Triggering Receptor Expressed on Myeloid Cells-1 with Clinical Disease Activity in Inflammatory Bowel Disease

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

An Erratum to this article was published on 01 January 2009

Abstract

Although triggering receptor expressed on myeloid cells-1 (TREM-1) has recently been shown to be upregulated in the intestines of patients with inflammatory bowel disease (IBD), it remains unclear whether serum-soluble TREM-1 (sTREM-1) level reflects disease activity in patients with IBD. This study aimed to evaluate the correlation of sTREM-1 level with disease activity in IBD. We prospectively enrolled consecutive patients with IBD and assessed their clinical disease activity using the guidelines of the American College of Gastroenterology. At the time that disease activity was assessed, sTREM-1 level (using an enzyme-linked immunosorbent assay method) and other laboratory findings including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were also measured. A total of 31 patients with ulcerative colitis (UC) and 22 with Crohn’s disease (CD) were enrolled. The mean sTREM-1 level in patients with either UC (60.4 ± 41.8 pg/ml) or CD (66.5 ± 42.4 pg/ml) was significantly higher than in healthy controls (0.6 ± 1.4 pg/ml) (P = 0.003 and P = 0.002, respectively). In patients with UC, sTREM-1 level was more highly correlated with disease activity (r = 0.849) than was ESR (r = 0.619) or CRP level(r = 0.546). Moreover, sTREM-1 level correlated well with disease activity irrespective of disease extent. In patients with CD, sTREM-1 level was lower in those with remission compared with those without (46.8 ± 35.3 pg/ml versus 77.8 ± 43.1 pg/ml), but this trend did not reach statistical significance (P = 0.100). The results of our study suggest that sTREM-1 could be a potential marker for disease activity in IBD patients, especially those with UC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hendriksen C, Kreiner S, Binder V. Long term prognosis in ulcerative colitis—based on results from a regional patient group from the county of Copenhagen. Gut. 1985;26:158–163. doi:10.1136/gut.26.2.158.

    Article  PubMed  CAS  Google Scholar 

  2. Stonnington CM, Phillips SF, Zinsmeister AR, Melton LJ III. Prognosis of chronic ulcerative colitis in a community. Gut. 1987;28:1261–1266. doi:10.1136/gut.28.10.1261.

    Article  PubMed  CAS  Google Scholar 

  3. Munkholm PLE, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol. 1995;30:699–706. doi:10.3109/00365529509096316.

    Article  PubMed  CAS  Google Scholar 

  4. Moum B, Ekbom A, Vatn MH, et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn’s disease. Results of a large, prospective population-based study in southeastern Norway, 1990–93. Scand J Gastroenterol. 1997;32:1005–1012. doi:10.3109/00365529709011217.

    Article  PubMed  CAS  Google Scholar 

  5. Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard NH. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000;95:359–367.

    PubMed  CAS  Google Scholar 

  6. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426–431. doi:10.1136/gut.2005.069476.

    Article  PubMed  CAS  Google Scholar 

  7. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2007;25:247–255.

    Article  PubMed  CAS  Google Scholar 

  8. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661–665. doi:10.1097/00054725-200409000-00026.

    Article  PubMed  Google Scholar 

  9. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol. 2000;164:4991–4995.

    PubMed  CAS  Google Scholar 

  10. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature. 2001;410:1103–1107. doi:10.1038/35074114.

    Article  PubMed  CAS  Google Scholar 

  11. Gibot S, Kolopp-Sarda MN, Béné MC, et al. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med. 2004;141:9–15.

    PubMed  CAS  Google Scholar 

  12. Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med. 2004;350:451–458.

    Article  PubMed  CAS  Google Scholar 

  13. Koussoulas V, Vassiliou S, Demonakou M, et al. Soluble triggering receptor expressed on myeloid cells (sTREM-1): a new mediator involved in the pathogenesis of peptic ulcer disease. Eur J Gastroenterol Hepatol. 2006;18:375–379. doi:10.1097/00042737-200604000-00010.

    Article  PubMed  Google Scholar 

  14. Schenk M, Bouchon A, Seibold F, Mueller C. TREM-1—expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J Clin Invest. 2007;117:3097–3106. doi:10.1172/JCI30602.

    Article  PubMed  CAS  Google Scholar 

  15. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2–6. Discussion 16–19.

    Article  PubMed  CAS  Google Scholar 

  16. Hanauer SB, Sandborn W. Management of Crohn’s disease in adults. Am J Gastroenterol. 2001;96:635–643. doi:10.1111/j.1572-0241.2001.03671.x.

    Article  PubMed  CAS  Google Scholar 

  17. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371–1385. doi:10.1111/j.1572-0241.2004.40036.x.

    Article  PubMed  Google Scholar 

  18. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521–533. doi:10.1038/nri1132.

    Article  PubMed  CAS  Google Scholar 

  19. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307:1920–1925. doi:10.1126/science.1106442.

    Article  PubMed  CAS  Google Scholar 

  20. Radsak MP, Salih HR, Rammensee HG, Schild H. Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: differential regulation of activation and survival. J Immunol. 2004;172:4956–4963.

    PubMed  CAS  Google Scholar 

  21. Tzivras M, Koussoulas V, Giamarellos-Bourboulis EJ, et al. Role of soluble triggering receptor expressed on myeloid cells in inflammatory bowel disease. World J Gastroenterol. 2006;12:3416–3419.

    PubMed  CAS  Google Scholar 

  22. Radsak MP, Taube C, Haselmayer P, et al. Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease. Clin Dev Immunol. 2007;52040:2007.

    Google Scholar 

  23. Yasuda T, Takeyama Y, Ueda T, et al. Increased levels of soluble triggering receptor expressed on myeloid cells-1 in patients with acute pancreatitis. Crit Care Med. 2008;36:2048–2053.

    Article  PubMed  CAS  Google Scholar 

  24. Sachar DB, Smith H, Chan S, Cohen LB, Lichtiger S, Messer J. Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease. J Clin Gastroenterol. 1986;8:647–650. doi:10.1097/00004836-198612000-00011.

    Article  PubMed  CAS  Google Scholar 

  25. Cross CE, Halliwell B, Borish ET, et al. Oxygen radicals and human disease. Ann Intern Med. 1987;107:526–545.

    PubMed  CAS  Google Scholar 

  26. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med. 1989;320:365–376.

    PubMed  CAS  Google Scholar 

  27. Dagli U, Balk M, Yücel D, et al. The role of reactive oxygen metabolites in ulcerative colitis. Inflamm Bowel Dis. 1997;3:260–264. doi:10.1002/ibd.3780030404.

    Article  Google Scholar 

  28. Oshitani N, Kitano A, Okabe H, Nakamura S, Matsumoto T, Kobayashi K. Location of superoxide anion generation in human colonic mucosa obtained by biopsy. Gut. 1993;34:936–938. doi:10.1136/gut.34.7.936.

    Article  PubMed  CAS  Google Scholar 

  29. Holmes EW, Yong SL, Eiznhamer D, Keshavarzian A. Glutathione content of colonic mucosa: evidence for oxidative damage in active ulcerative colitis. Dig Dis Sci. 1998;43:1088–1095. doi:10.1023/A:1018899222258.

    Article  PubMed  CAS  Google Scholar 

  30. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984;87:1344–1350.

    PubMed  CAS  Google Scholar 

  31. Grisham MB, Granger DN. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci. 1988;33:6S–15S. doi:10.1007/BF01538126.

    Article  PubMed  CAS  Google Scholar 

  32. Simmonds NJ, Allen RE, Stevens TR, Van Someren RN, Blake DR, Rampton DS. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology. 1992;103:186–196.

    PubMed  CAS  Google Scholar 

  33. Sedghi S, Fields JZ, Klamut M, et al. Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis. Gut. 1993;34:1191–1197. doi:10.1136/gut.34.9.1191.

    Article  PubMed  CAS  Google Scholar 

  34. Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol. 2007;102:2058–2069. doi:10.1111/j.1572-0241.2007.01343.x.

    Article  PubMed  CAS  Google Scholar 

  35. Saverymuttu SH, Hodgson HJ, Chadwick VS, Pepys MB. Differing acute phase responses in Crohn’s disease and ulcerative colitis. Gut. 1986;27:809–813. doi:10.1136/gut.27.7.809.

    Article  PubMed  CAS  Google Scholar 

  36. Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-reactive protein in Crohn’s disease and ulcerative colitis. Eur J Clin Invest. 1982;12:351–360. doi:10.1111/j.1365-2362.1982.tb02244.x.

    Article  PubMed  CAS  Google Scholar 

  37. Solem CA, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707–712. doi:10.1097/01.MIB.0000173271.18319.53.

    Article  PubMed  Google Scholar 

  38. Florin TH, Paterson EW, Fowler EV, Radford-Smith GL. Clinically active Crohn’s disease in the presence of a low C-reactive protein. Scand J Gastroenterol. 2006;41:306–311. doi:10.1080/00365520500217118.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the Yonsei University College of Medicine, Internal Medicine Research Grant 2006 and Korean Abbott Research Fund 2007.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jae Hee Cheon.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s10620-008-0679-y

Rights and permissions

Reprints and permissions

About this article

Cite this article

Park, J.J., Cheon, J.H., Kim, B.Y. et al. Correlation of Serum-Soluble Triggering Receptor Expressed on Myeloid Cells-1 with Clinical Disease Activity in Inflammatory Bowel Disease. Dig Dis Sci 54, 1525–1531 (2009). https://doi.org/10.1007/s10620-008-0514-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-008-0514-5

Keywords

Navigation